Study on Prevention of Gastric Cancer by Early Detection of Helicobacter pylori Infection and Its Eradication(2nd-Term Comprehensive 10-Year Strategy for Cancer Control from the Ministry of Health and Welfare of Japan)

Study on Prevention of Gastric Cancer by Early Detection of Helicobacter pylori Infection and Its Eradication(2nd-Term Comprehensive 10-Year Strategy for Cancer Control from the Ministry of Health and Welfare of Japan) - JITHP: Japanese Intervention Trial of H. pylori.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000191

Enrollment

750

Registered

2007-01-31

Start date

1995-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastritis

Interventions

* Lansoprazole(30mg/day x 7days) * Clarithromycin(400mg/day x 7days) * Amoxicillin(1,500mg/day x 7days)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients who do not have the anamnesis of gastrointestinal ulcer or malignant gastric tumor endoscopically diagnosed to be H. pylori-positive in the cultivation of biopsy sample and who satisfy the following criteria are enrolled: 1) Hospitalized or out-patient:Irrespective 2) Age:20 to 59 years old 3) Sex:Irrespective 4) Patients who consented to be followed-up for 8 years

Exclusion criteria

Exclusion criteria: 1) Patients who suffer from acuteulcer(AGML, etc,) and gastrointestinal ulcer (stage A1-S2) 2)Patients who suffer from pyloric stenosis, perforation, profuse hemorrhage, etc, and indications of surgical therapy 3)Patients with the anamnesis of gastrectomy or vagotomy 4)Patients with gastric adenoma or active malignant tumor in the stomach and other organs 5)Patients with severe complications (cardiac diseases, hepatic diseases, renal diseases, hematological diseases, etc.) 6)Patients who are the continuous users of possibly ulcerogenic drugs (for instance, steroids, non-steroids, salicylates, etc.) 7)Patients who are or may be pregnant, who are lactating and who wish to become pregnant before and after eradication treatment 8)Patients who have the anamnesis of hypersensitivity to antibiotics, proton pump inhibitors, or other drugs which will be used in the present study 9)Patients who have been judged by the physician in charge to be inappropriate as subjects from other reasons

Design outcomes

Primary

Measure	Time frame
The degree of atrophic gastritis	—

Countries

Japan

Contacts

Public ContactDaizo Saito

National Cancer Center Hospital(NCCH) Endoscopy Division

dsaitoh@ncc.go.jp03-3542-2511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026